CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

DeVaney led CVS Caremark sales and account management as president, Employer & Health Plans. CVS Health. This story was ...

In the latest executive shakeup at CVS, the pharmacy giant has named a new president of its pharmacy benefit management ...

A reescalating battle between pharmaceutical companies and pharmacy benefit managers is brewing in Washington, D.C., as ...

Recent health news highlights disruptions in HIV and malaria supply chains due to a U.S. aid freeze, FDA's approval of a new ...

CVS Health said on Friday it has cut bonuses for some employees because of its low profit levels last year, as the healthcare ...

CVS Health (NYSE: CVS) announced Friday that it has reduced employee bonuses due to lower-than-expected profits in 2024. The healthcare giant faced mounting costs, particularly from its Medicare plans ...

A CVS spokesperson said the Emory collaboration is the first time MinuteClinic has expanded into primary care services in ...

CVS Pharmacy thinks it has found a solution to customer complaints about locked display cases - but the cure may be worse ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted earnings for 2025 to land in a range between $5.75 and $6 per share. That's ...